Robert McArthur, MD
Rheumatology · Norman, OKNPI 1508864877
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.2% of the total across 233 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,165 and has fallen 77.3% since, to $264 in 2025. That places this record below the midpoint for rheumatology clinicians in OK, where the typical reported total is $4,359.
Across 233 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$545
- AbbVie$525
- UCB, Inc.$442
- Lilly USA, LLC$358
- Amgen$347
- E.r. Squibb & Sons, L.L.C.$299
- plus $1K from 17 others
Across 2 payments — averaging $435.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$747
- Jazz Pharmaceuticals Inc.$125
What the payments were for
- Food & beverage$3,40292%
- Education$2868%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 31 | $545 |
| AbbVie | 28 | $525 |
| UCB, Inc. | 32 | $442 |
| Lilly USA, LLC | 22 | $358 |
| Amgen(2 entities) | 20 | $347 |
| E.r. Squibb & Sons, L.L.C. | 21 | $299 |
| AstraZeneca | 13 | $218 |
| Pfizer | 25 | $217 |
| Novartis | 9 | $162 |
| Boehringer Ingelheim | 6 | $144 |
| Regeneron Healthcare Solutions, Inc. | 5 | $133 |
| GSK | 5 | $64 |
| Radius Health, Inc. | 3 | $39 |
| ANI Pharmaceuticals, Inc. | 2 | $37 |
| Sandoz | 2 | $34 |
| Genentech USA, Inc. | 2 | $26 |
| Sanofi | 1 | $21 |
| Bristol Myers Squibb | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Organon | 1 | $12 |
| Sobi, Inc | 1 | $12 |
| Medtronic | 1 | $11 |
| Pacira Therapeutics, Inc. | 1 | $11 |
How this compares
$3,688 in reported general payments places this provider in the 45th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 61 | $412,412 |
| Enbrel SureclickEtanercept | 37 | $328,194 |
| Xeljanz XrTofacitinib Citrate | 38 | $236,154 |
| Orencia ClickjectAbatacept | 20 | $141,827 |
| XeljanzTofacitinib Citrate | 11 | $63,572 |
| SavellaMilnacipran Hcl | 18 | $14,359 |
| MethotrexateMethotrexate Sodium | 411 | $8,395 |
| Pregabalin | 129 | $5,411 |
| Celecoxib | 269 | $4,745 |
| Hydroxychloroquine Sulfate | 105 | $4,310 |
| Tramadol Hcl | 281 | $3,974 |
| Duloxetine Hcl | 188 | $3,646 |
| Leflunomide | 84 | $3,364 |
| Azathioprine | 59 | $2,225 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 76 | $1,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerXeljanz | $217 | $63,57211 claims |
| AbbVieSavella | $525 | $14,35918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 67 rheumatology providers in Oklahoma.
Other rheumatology in Norman
- Sobia AhmadNorman$9K
- Joan MerrillOklahoma City$864K
- Latisha HeinlenOklahoma City$675K
- Debbie FoleyTulsa$281K
- Mohammad KhanOklahoma City$94K
- Cristina ArriensOklahoma City$82K
- Tommie SimonLawton$55K
- Mary Hinojos MamutTulsa$21K
- Drew HuffmanMoore$20K
- Manuel CalvinTulsa$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.